Get the content you want anytime you want.
REGISTER NOW | SIGN IN

Select coverage from ID Week 2016 is included below:

Ceftazidime-Avibactam in Different Patient Populations
Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, explains how her future research aims to understand the effects of ceftazidime-avibactam in different patient populations.
What Have We Learned About Ceftazidime-Avibactam?
Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses the significance of the findings of her research on Ceftazidime-Avibactam.
Using Ceftazidime-Avibactam to Treat Antibiotic-Resistant Infections
Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses her findings regarding patients treated with ceftazidime-avibactam for carbapenem-resistant Enterobacteriaceae infections and carbapenem-resistant Pseudomonas infections.
Evaluating CAZ-AVI Against Antibiotic-Resistant Gram-Negative Organisms
Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses her research on the efficacy of ceftazidime-avibactam against infections caused by gram-negative organisms.
For Which Infections is Ceftazidime-Avibactam Approved?
Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, explains for which infections ceftazidime-avibactam is approved by the US Food and Drug Administration.
Assessing the Clinical Wellbeing of SSTI Patients
Michael D. Nailor, PharmD, BCPS-AQ ID, clinical associate professor at the University of Connecticut School of Pharmacy, clinical specialist in infectious diseases at Hartford Hospital, and director of Infectious Disease Residency program at Hartford Hospital, explains how his research can assess clinical well-being of patients with skin and soft tissue infections.
Reducing the Incidence of Acute Kidney Injury from Vancomycin & Pip/Tazo
Megan Luther, PharmD, Advanced Health Services research fellow, Providence Veterans Affairs Medical Center, University of Rhode Island, College of Pharmacy, discusses potential strategies to reduce incidence of acute kidney injuries due to vancomycin and pip/tazo combination therapy.
What's Next for the CORE Healthy Aging Initiative?
Oluwatoyin (Toyin) Adeyemi, MD, attending physician of infectious diseases, at Cook County Health and Hospital System, discusses the next steps in implementing activities for the CORE Healthy Aging Initiative.
FEATURED
We break down our top HIV news stories of 2017. Did you read them all?
x